Citadel Advisors
JSPR icon

Citadel Advisors’s Jasper Therapeutics JSPR Stock Holding History

Citadel Advisors’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$40.4K Sell
46,100
-2,100
-4% -$2.92K ﹤0.01% 12487
2025
Q4 		$88.2K Buy
48,200
+3,700
+8% +$7.43K ﹤0.01% 11734
2025
Q3 		$106K Buy
+44,500
New +$135K ﹤0.01% 11816
2025
Q2 		– Sell
-8,000
Closed -$34.4K – 13844
2025
Q1 		$34.4K Buy
8,000
+6,500
+433% +$43.3K ﹤0.01% 12685
2024
Q4 		$32.1K Sell
1,500
-2,400
-62% -$50K ﹤0.01% 12804
2024
Q3 		$73.4K Buy
+3,900
New +$77.7K ﹤0.01% 11500
2024
Q2 		– Sell
-2,800
Closed -$82.2K – 14880
2024
Q1 		$82.2K Sell
2,800
-1,120
-29% -$19.9K ﹤0.01% 11623
2023
Q4 		$30.9K Sell
3,920
-2,970
-43% -$19.9K ﹤0.01% 12240
2023
Q3 		$48.2K Buy
6,890
+4,940
+253% +$60.3K ﹤0.01% 11794
2023
Q2 		$26.7K Buy
1,950
+1,300
+200% +$19.3K ﹤0.01% 12476
2023
Q1 		$11.8K Buy
+650
New +$12K ﹤0.01% 13456
2022
Q3 		– Sell
-1,610
Closed -$31K – 13125
2022
Q2 		$31K Sell
1,610
-550
-25% -$15.7K ﹤0.01% 12198
2022
Q1 		$77K Buy
+2,160
New +$97.3K ﹤0.01% 12502

Other funds holding JSPR

VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Citadel Advisors's JSPR Position: Q4 2025 in Review

Citadel Advisors sold out of Jasper Therapeutics (JSPR) in Q4 2025, closing a stake of 589,449 shares — an estimated $1.18M sold.

Citadel Advisors first reported a position in JSPR in Q1 2021 and held it in 18 quarters. The position peaked at $29.2M in Q3 2021. 55 funds tracked by Wall St. Rank hold JSPR as of Q4 2025.

  • Citadel Advisors reported no remaining Jasper Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Citadel Advisors sold 589,449 Jasper Therapeutics shares in Q4 2025, an estimated $1.18M.
  • Citadel Advisors first reported a position in Jasper Therapeutics in Q1 2021 and held it in 18 quarters.
  • Citadel Advisors's Jasper Therapeutics position peaked at $29.2M in Q3 2021.
  • 55 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q4 2025.

Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.